^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Drug:Zevalin (ibritumomab tiuxetan) (CD20 inhibitor, Ionizing radiation emitter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Zevalin is indicated in adults...[90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with:…relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL)...previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Follicular Lymphoma...Other recommended regimens...Ibritumomab (category 2B)